SUSAN ABUGHOSH to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications SUSAN ABUGHOSH has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
4.366
-
Group-based trajectory modeling to identify longitudinal patterns and predictors of adherence among older adults on concomitant triple therapy (oral antidiabetic, renin-angiotensin-system antagonists, statins). J Manag Care Spec Pharm. 2025 Apr; 31(4):396-405.
Score: 0.581
-
Evaluating Adherence to Concomitant Diabetes, Hypertension, and Hyperlipidemia Treatments and Cardiovascular Outcomes Among Elderly Patients Using Marginal Structural Modeling. High Blood Press Cardiovasc Prev. 2022 Nov; 29(6):601-610.
Score: 0.488
-
Evaluating adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments and intermediate outcomes among elderly patients using marginal structural modeling. Pharmacotherapy. 2022 07; 42(7):518-528.
Score: 0.478
-
Using group-based trajectory modeling to characterize the association of past ACEIs/ARBs adherence with subsequent statin adherence patterns among new statin users. J Am Pharm Assoc (2003). 2021 Nov-Dec; 61(6):829-837.e2.
Score: 0.449
-
Identifying adherent patients to newly initiated statins using previous adherence to chronic medications. J Manag Care Spec Pharm. 2021 Feb; 27(2):186-197.
Score: 0.435
-
Impact of a motivational interviewing intervention targeting statins on adherence to concurrent hypertension or diabetes medications. Patient Educ Couns. 2021 07; 104(7):1756-1764.
Score: 0.433
-
Patient-reported barriers to statin adherence: Excerpts from a?motivational interviewing intervention in older adults. J Am Pharm Assoc (2003). 2021 Jan-Feb; 61(1):60-67.e1.
Score: 0.426
-
Evaluating trajectories of statin adherence after a motivational interviewing intervention. J Am Pharm Assoc (2003). 2020 Nov - Dec; 60(6):892-898.
Score: 0.419
-
Enhancing Statin Adherence Using a Motivational Interviewing Intervention and Past Adherence Trajectories in Patients with Suboptimal Adherence. J Manag Care Spec Pharm. 2019 Oct; 25(10):1053-1062.
Score: 0.397
-
Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. J Manag Care Pharm. 2004 Sep-Oct; 10(5):404-11.
Score: 0.139
-
Patterns of Lipid Lowering Therapy Use Among Older Adults in a Managed Care Advantage Plan in the United States. J Pharm Pract. 2024 Feb; 37(1):123-131.
Score: 0.123